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ABSTRACT: The successful application of gene therapy
approaches is highly dependent on the efficient delivery of
nucleic acids into target cells. In the present study, new
peptide-based nonviral systems were developed to enhance
plasmid DNA and siRNA delivery, aiming at generating
appropriate gene delivery and gene silencing tools for
preclinical and clinical application. For this purpose, a new
cell-penetrating peptide derived from the wild-type S413-PV
peptide was synthesized through the addition of a five-histidine
tail to its N-terminus (H5-S413-PV), and its ability to mediate
gene expression and gene silencing was evaluated and compared to that of the wild-type peptide. The histidine-enriched peptide,
H5-S413-PV, proved to be generally more efficient and less toxic than the wild-type peptide in the delivery of plasmid DNA. In
addition, complexes of H5-S413-PV with siRNAs, but not of S413-PV, were efficiently internalized by cells and presented high
knockdown activity (63%). Interestingly, systems containing the S413-PV or the H5-S413-PV peptide exhibited superior biological
activity when compared to those containing the reverse NLS or scrambled peptides, suggesting that both the cell-penetrating
sequence and the NLS of the S413-PV peptide influence the competence of binary and ternary complexes to accomplish nucleic
acid delivery. In order to unravel the cancer therapeutic potential of formulations with the histidine-enriched peptide, their
efficiency to mediate silencing of the oncogenic protein survivin was evaluated. As opposed to complexes with the wild-type
peptide, H5-S413-PV complexes showed the ability to promote a high survivin knockdown at the level of both protein (44%) and
mRNA (73%), in HT1080 cells.
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■ INTRODUCTION
In order to improve the clinical efficacy of gene-based
therapeutic strategies, a great deal of effort has been expended
on the discovery of potent therapeutic genes or gene-
modulating molecules and on the enhancement of the
efficiency of gene delivery systems. Viral and nonviral systems
have been developed to mediate the delivery of plasmid DNA
and siRNAs to target cells. However, gene therapy approaches
that are both highly efficient and clinically viable are still
scarce.1−3 Cell-penetrating peptides (CPPs) have been
extensively applied for nucleic acid delivery, using both covalent
and noncovalent association strategies.4 While the covalent
linkage of CPPs to nucleic acids allows the formation of small,
monomeric conjugates of known stoichiometry with high
reproducibility, the preparation of noncovalent complexes is
technically simpler, originates nanoparticles with a net positive
charge, and decreases the risk of altering the biological activity
of the cargo.4,5
Many CPPs are derived from transduction domains of
proteins, which are known for their remarkable properties of
cell penetration, although model and designed CPPs have also
been generated. Several modifications of naturally occurring
sequences have been introduced in CPPs in order to achieve
higher transfection efficiencies mediated by CPP-based delivery
systems. A new HIV-1 Tat peptide-based gene delivery system
was designed by fusing the original Tat with cysteine and
histidine residues.6 The rationale behind these modifications
was based on the features of these amino acids. The cysteine
residue−disulfide interactions allow the stabilization and
protection of the CPP−nucleic acid complexes in the
extracellular medium, while their lability in the endosomal
reducing environment contributes to nucleic acid release.
However, the specific pKa of the histidine imidazole group,
being close to the endosomal pH, allows protonation and leads
to osmotic swelling, mimicking the proton−sponge effect
observed with polyethyleneimine (PEI), thus facilitating nucleic
acid release.6−8 Proton−sponge activity has been exploited in
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the CPP field by using peptides that partially mimic this feature.
With this purpose, lysine and histidine residues have been
added to template amphipathic peptides rich in alanines and
leucines.9 Lysines were expected to promote DNA condensa-
tion, conferring positive charge to the peptides, while histidines
might favor the endosomal escape of DNA by the above-
mentioned process.8 Various numbers of lysine and histidine
residues were included in the original peptide sequence, either
by replacement of a neutral amino acid or by the addition of a
new residue to the sequence. The transfection efficiency
showed the dependence on the number of histidine residues
and on their position in the sequence, as well as on the pH at
which the peptides change from an in-plane to a trans-
membrane alignment, the most efficient peptides being those
containing 4 to 5 histidines located in the polar face of the α−
helix structure.9 On the basis of all these findings, modifications
were performed on the S413-PV peptide, a dermaseptin derived
peptide fused to the nuclear localization sequence of the SV40
large T antigen,10 which has been extensively studied in our
laboratory. In this regard, a S413-PV analogue with a five-
histidine tail at the N-terminus was synthesized, originating a
new peptide called herein H5-S413-PV. Following our previous
work on the development of S413-PV peptide-based vectors for
nucleic acid delivery9,10 and aiming at identifying the molecular
features responsible for efficient nucleic acid delivery, the new
peptide was here compared with the wild-type (S413-PV) and
its scrambled (S413-PVscr) and reverse NLS (S413-PVrev)
analogues (Table 1), in terms of its ability to efficiently deliver
plasmid DNA and siRNA to different cell lines. Ternary
systems produced through the addition of dioleoyltrimethy-
lammoniumpropane: dioleoylphosphatidylethanolamine (DO-
TAP:DOPE) liposomes to the CPP-nucleic acid complexes
were also assayed since previous work had revealed that the
association of these vesicles with CPP complexes led to the
formation of more efficient plasmid delivery systems.11,12
Our results showed that the histidine tail preserves or
improves the S413-PV peptide’s ability to efficiently deliver
reporter plasmid DNA and siRNAs to different cell lines. In
order to test the efficiency of the new CPP-based delivery
systems to silence endogenous genes, the survivin gene was
selected as a target. Survivin is a member of the IAP family,
playing an important role in cell proliferation and inhibition of
apoptosis.13−22 Because of its overexpression in cancer cells and
no or very low expression in normal cells, survivin constitutes a
particularly promising target for cancer therapy. Moreover,
survivin renders malignant cells resistant to conventional
antitumoral treatments, by counteracting pro-apoptotic stimuli
and, therefore, enhancing cancer cell survival.11,21−25
Altogether, the present findings open a new window to
extend the use of CPPs, including the S413-PV peptide and its
histidine derivative, as appropriate tools for nucleic acid
delivery, with potential for clinical applications in different
pathologies, such as cancer.
■ MATERIALS AND METHODS
Materials. The cationic lipid 1,2-dioleoyl-3-trimethylammo-
nium-propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3-phos-
phoethanolamine (DOPE) were purchased from Avanti Polar
Lipids (Alabaster, AL, USA). The primers for survivin and for
HPRT-1 genes were predesigned by Qiagen (QuantiTect
Primer, Qiagen). The antibody antisurvivin was purchased from
Santa Cruz (Santa Cruz Biotechnology, Inc., Heidelberg,
Germany), and the remaining antibodies were obtained from
Sigma (St. Louis, MO, USA). The anti-GFP siRNA (5′-
GCAAGCUGACCCUGAAGUUCAU-3′) and Cy3-labeled
nonspecific siRNA sequence were purchased from Ambion
(Austin, TX, USA). The antisurvivin siRNA (5′-GGACCA-
CCGCAUCUCUACAdTdT-3′) and the nonsilencing siRNA
used as control were obtained from Dharmacon (Lafayette,
CO, USA). Fmoc-protected amino acids, Fmoc-Rink amide-
MBHA LL resin (0.36 mmol/g) and coupling reagent O-
(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium-hexafluoro-
phosphate (HBTU) were provided by Novabiochem (VWR
International, Portugal). All the other chemicals were of the
highest grade.
Peptide Synthesis. Peptide synthesis was performed using
a Liberty Microwave Peptide Synthesizer (CEM Corporation,
Mathews, NC, USA). Peptide analysis by HPLC was done
using a Hitachi-Merck LaChrom Elite system equipped with a
quaternary pump, a thermostatted (Peltier effect) automated
sampler, and a diode-array detector (DAD). An LCQ-DecaXP
LC-MS system from ThermoFinnigan, equipped with both a
DAD detector and an electrospray ionization-ion trap mass
spectrometer (ESI/IT MS), was also used for peptide analysis.
Peptide quantitation was performed by measuring the
absorbance at 280 nm in a Helios Gama spectrophotometer
(Spectronic Unicam).
The peptide (C-terminal amide) was assembled by Fmoc/
tBu solid-phase peptide synthesis (SPPS) methodologies
assisted with microwave (MW) energy.26 The resin was
preconditioned for 15 min in N,N-dimethylformamide
(DMF) and then transferred into the MW-reaction vessel.
The initial Fmoc deprotection step was carried out using 20%
piperidine in DMF containing 0.1 M of 1-hydroxybenzotriazole
(HOBt) in two MW irradiation pulses: 30 s at 24 W plus 3 min
at 28 W, in both cases temperature being no higher than 75 °C.
The C-terminal amino acid was then coupled to the
deprotected Rink amide resin, using 5 mol equivalent (eq) of
the Fmoc-protected amino acid in DMF (0.2 M), 5 eq of 0.5 M
HBTU/HOBt in DMF, and 10 eq of 2 M N-ethyl-N,N-
diisopropylamine (DIPEA) in N-methylpyrrolidone (NMP);
the coupling step was carried out for 5 min at 35 W MW
irradiation, with maximum temperature reaching 75 °C. The
remaining amino acids were sequentially coupled in the C→N
direction by means of similar deprotection and coupling cycles,
except for the incorporation of (i) Fmoc-Arg(Pbf)-OH, whose
coupling was done in two steps, 25 min with no MW irradiation
(room temperature) followed by 5 min coupling at 25 W; (ii)
Fmoc-Cys(Trt)-OH, Fmoc-Trp(Boc)-OH, and Fmoc-His-
(Trt)-OH, all coupled also in two steps, first with 2 min
coupling without MW irradiation (room temperature), then
followed by 4 min coupling at 25 W, with maximum
temperature reaching 50 °C. Double-coupling was employed
with all lysines in the sequence (residues 5, 6, 7, 10, and 14),
incorporated as Fmoc-Lys(Boc)-OH. Following completion of
the sequence assembly, the peptide was released from the resin
Table 1. Sequences of the S413-PV and Derived Peptides
Used in the Present Study
S413-PV ALWKTLLKKVLKAPKKKRKVC-NH2
H5-S413-PV HHHHHALWKTLLKKVLKAPKKKRKVC-NH2
S413-PVscr KTLKVAKWLKKAKPLRKLVKC-NH2
S413-PVrev ALWKTLLKKVLKAVKRKKKPC-NH2
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with concomitant removal of side-chain protecting groups, by a
3 h acidolysis at room temperature using a trifluoroacetic acid
(TFA)-based cocktail27,28 containing thioanisole, 1,2-ethanedi-
thiol, and anisole as scavengers (TFA/thioanisole/1,2-ethane-
dithiol/anisole 90:5:3:2 v/v/v/v). Crude product was purified
by reverse-phase liquid chromatography to give the target
peptide, as confirmed by HPLC, LC-ESI/IT MS, and AAA.
Cells. HeLa cells (human epithelial cervical carcinoma) and
A549 cells (human epithelial lung adenocarcinoma) were
maintained at 37 °C, under 5% CO2, in Dulbecco’s modified
Eagle’s medium-high glucose (DMEM; Sigma) supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (FBS;
Biochrom KG) and 100 units penicillin and 100 μg of
streptomycin (Sigma) per mL. HT1080 cells (human
fibrosarcoma) were maintained at 37 °C, under 5% CO2, in
Dulbecco’s modified Eagle’s low glucose medium (DMEM-LG;
Sigma) supplemented with 10% (v/v) heat-inactivated fetal
bovine serum (FBS; Biochrom KG) and 100 units penicillin
and 100 μg of streptomycin (Sigma) per mL.
For flow cytometry and cell viability experiments, 1.0 × 105
HeLa, A549, or HT1080 cells/well were seeded onto 12-well
plates; for fluorescence microscopy studies, 0.2 × 105 HT1080
cells/well were plated onto 8-well chambered coverslips (Lab-
Tek II Chamber Slide System Nunc). For QRT-PCR and
Western blot experiments, 1.0 × 105 HeLa, A549, and HT1080
cells/well were plated onto 6-well plates. Cells were plated 24
hours prior to incubation with the complexes.
Cationic Liposome Preparation. Small unilamellar
vesicles (SUV) were prepared by extrusion of multilamellar
vesicles composed of the cationic lipid DOTAP and DOPE at a
1:2 molar ratio. Briefly, lipid solutions in chloroform were
mixed at the desired molar ratio and dried under vacuum, at
room temperature, using a rotary evaporator. The dried lipid
films were then hydrated with 1.0 mL of high purity water, and
the obtained multilamellar vesicles were briefly sonicated and
extruded 21 times through two stacked polycarbonate filters
(50 nm pore diameter) using a Liposofast device (Avestin).
The lipid concentration of the resulting SUV was determined
by the Bartlett method,29 which measures the inorganic
phosphate released after the hydrolysis of dried phospholipids,
at 180 °C, in 70% HClO4.
30
Complex Preparation. The complexes (binary and
ternary) were prepared in HEPES-buffered saline solution
(HBS; 140 mM NaCl and 10 mM HEPES, pH 7.4). Binary
complexes were produced by gently mixing the plasmid DNA
(0.5 μg) or the siRNA (25 pmol) with each of the CPPs, at the
desired charge ratio, followed by 15 min (plasmid DNA
complexes) or 30 min (siRNA complexes) of incubation at
room temperature. Ternary plasmid DNA complexes were
obtained by gently mixing peptide/pDNA complexes, prepared
at the desired charge ratio, with DOTAP:DOPE liposomes.
Mixtures were then incubated for 15 min, at room temperature.
SiRNA formulations containing both CPP and cationic
liposomes were prepared following two different protocols,
which involved the addition of each CPP to the siRNAs,
followed by the addition of the cationic liposomes (herein
termed CPP/siRNA/DOTAP:DOPE complexes), or the
mixing of the CPPs with the cationic liposomes, before the
addition of the siRNAs (herein termed CPP/DOTAP:DOPE/
siRNA complexes). After the addition of each component, the
mixtures were gently mixed and incubated for 30 min at room
temperature to allow for the formation of the complexes
exhibiting the desired charge ratios.
Physicochemical Characterization of Complexes.
Complexes were characterized with respect to their size by
photon correlation spectroscopy-based technique (PCS) using
a Coulter N4 Plus (Coulter Corporation, Miami, FL, USA).
PCS uses autocorrelation spectroscopy of scattered laser light
to determine its time-dependent fluctuations resulting from the
Brownian motion of particles in suspension. The light intensity
scattered at a given angle is detected by a photomultiplier (at
fixed angle of 90°) whose output current is passed to an
autocorrelator, which analyses time dependence, determining
the rate of diffusion or Brownian motion of the particles and
hence their size.31 Complexes were prepared immediately
before analysis. All complexes showed a polymodal size
distribution.
Zeta potential measurements of different complexes were
performed using a Nano ZS, ZN 3500 (Malvern Instruments,
UK). The Nano ZS is a laser-based multiangle particle
electrophoresis analyzer that measures the electrophoretic
mobility and zeta potential distribution simultaneously with
the hydrodynamic size of particles in suspension. CPP/DNA
and CPP/DNA/liposomes complexes were prepared immedi-
ately before analysis. Samples of the prepared complexes were
placed in the DTS 1060C measuring cell, whose position was
adjusted to cover a previously determined stationary layer, and
an electric current of 3.0 mA was applied.
Measurements were recorded, and the zeta potential was
calculated for each scattering angle (8.6°, 17.1°, 25.6°, and
34.2°). Data represent the mean ± SD obtained for the
different angles of three measurements. All complexes showed a
unimodal distribution for the zeta potential
Cell Transfection. Twenty-four hours after plating, cells
were incubated with 100 μL of the complexes (binary and
ternary) containing plasmid DNA (1 μg/mL) or siRNA (50
nM), in a final volume of 500 μL of antibiotic- and serum-free
OptiMEM (Invitrogen, CA, USA), for 4 h at 37 °C. After this
incubation period, the transfection medium was replaced with
fresh medium containing 10% (v/v) FBS plus antibiotics, and
the cells were further incubated for 44 h to allow gene
expression/silencing. The efficiency of transfection and knock-
down mediated by the different complexes was evaluated by
analyzing GFP expression by flow cytometry, as described
below.
Analysis of GFP Expression by Flow Cytometry. Flow
cytometry analysis of GFP expression was performed in live
cells using a Becton Dickinson FACSCalibur flow cytometer
(BD Biosciences, San Jose, CA, USA). Data were obtained and
analyzed using CellQuest software. Forty-eight hours after
transfection, the cells (HeLa, A549 or HT1080) were washed
once with PBS and detached with trypsin (10 min at 37 °C).
The cells were then further washed, resuspended in cold PBS,
and immediately analyzed. To discriminate between viable and
dead cells and to exclude doublets, cells were appropriately
gated by forward/side scatter and pulse width from a total of
10,000 events. The FITC bandpass filter was used in emission
detection. GFP expression was evaluated through the analysis
of the percentage of transfected cells and of the geometric
mean fluorescence intensity with respect to control cells
(nontransfected cells). GFP silencing was evaluated through
the analysis of the fluorescence intensity with respect to cells
treated with siRNA mut (scrambled sequence) complexes.
Analysis of siRNA Internalization and Intracellular
Distribution by Confocal Microscopy. HT1080 cells (0.2 ×
105 cells/well) were plated onto 8-well chambered coverslips.
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Following overnight culture, the cells were treated for 4 h with
the different delivery systems, formulated with Cy3-labeled
siRNAs (50 nM), in OptiMEM medium. After this period, or
following further 20 h of incubation in serum-containing
medium, cells were rinsed twice with PBS and incubated with
Hoechst 33342 dye (1 μg/mL, Molecular Probes, Eugene,
OR). Cells were then rinsed twice with PBS and directly
observed in the chambers in 0.5 mL of OptiMEM.
Fluorescence distribution inside live cells was analyzed under
a Zeiss Axiovert 200 M fluorescence microscope (Carl Zeiss,
Oberk), using the 60× oil immersion objective.
Extraction of RNA and cDNA Synthesis. RNA was
recovered from A549, HeLa, and HT1080 cells, 48 h after cell
transfection, using the MasterPure RNA Purification Kit
(Epicenter Biotechnologies, Madison, WI, USA) according to
the manufacturer’s instructions, and then treated with DNase I.
Briefly, cells were lysed using the Tissue and Cell Lysis Solution
from the MasterPure RNA Purification Kit containing
proteinase K, and cell lysates were collected to microcentrifuge
tubes. MPC Protein Precipitation Reagent was added to the
protein extract from the lysates. Then, 500 μL of isopropanol
was added to the recovered supernatant to promote total
nucleic acid precipitation, which was pelleted by centrifugation.
Removal of contaminating DNA from the RNA was then
performed by the addition of a DNase I solution and carrying
out another step of protein removal using MPC Protein
Precipitation Reagent. RNA was finally pelleted by centrifuga-
tion, rinsed twice with 70% ethanol, and resuspended in TE
buffer. After quantification, RNA was converted to cDNA using
the Superscript III First Strand Synthesis Kit (Invitrogen,
Karlsruhe, Germany), according to the manufacturer’s
instructions.
Quantitative Real Time Polymerase Chain Reaction
(QRT-PCR). Quantitative PCR was performed in an iQ 5
thermocycler using 96-well microtiter plates and the iQ SYBR
Green Supermix Kit, as described before.32 The primers for the
target gene (survivin) and the reference gene (HPRT-1) were
predesigned by Qiagen (QuantiTect Primer, Qiagen). Survivin
mRNA fold decrease with respect to control samples was
determined by the Pfaffl method,33 taking into consideration
the different amplification efficiencies of both genes in all
experiments. The amplification efficiency for each target or
reference gene was determined according to the equation: E =
10−1/S-1, where S is the slope of the obtained standard curve.
Western Blot Analysis. Seventy-two hours after trans-
fection of cells (HeLa, A549, or HT1080 cells) with the siRNA
complexes, total protein extracts were obtained using a lysis
buffer (50 mM NaCl, 50 mM EDTA, and 1% Triton X-100)
supplemented with a protease inhibitor cocktail (Sigma), 10
μg/mL DTT, and 1 mM PMSF. Protein content was
determined using the Bio-Rad DC protein assay (Bio-Rad).
For each sample, 20 μg of total protein was resuspended in
loading buffer (20% glycerol, 10% SDS, and 0.1% bromophenol
blue), incubated for 5 min at 95 °C, and loaded onto a 15%
polyacrylamide gel. After electrophoresis, the proteins were
blotted onto a PVDF membrane according to standard
protocols. After blocking in 5% nonfat milk, the membrane
was incubated overnight at 4 °C with the appropriate primary
antibody (antisurvivin 1:200, Santa-Cruz) and thereafter with
the appropriate secondary antibody (1:10000, Sigma) for 2 h at
room temperature. Equal protein loading was shown by
reprobing the membrane with an anti-α-tubulin antibody
(1:10000, Sigma) and with the appropriate secondary antibody.
After this incubation period, the membrane was washed several
times with saline buffer (TBS/T containing 25 mM Tris−HCl,
150 mM NaCl, 0.1% Tween, and 5 mg/mL nonfat powder
milk), incubated with ECF (alkaline phosphatase substrate; 20
μL of ECF/cm2 of membrane) for 5 min at room temperature,
and submitted to fluorescence detection at 570 nm using a
VersaDoc Imaging System Model 3000 (Bio-Rad). For each
membrane, the analysis of band intensity was performed using
Image J software (Wayne Rasband National Institutes of
Health, USA), and the survivin band intensities were
normalized to α-tubulin in each experiment.
Evaluation of Cell Viability. Cell viability was assessed
under the different experimental conditions by a modified
Alamar Blue assay, as described previously.34 Briefly, 48 h (for
flow cytometry and QRT-PCR analysis) or 72 h (for Western
blot analysis) after transfection, the cells were incubated with
DMEM (HeLa and A549 cells) or DMEM-LG (HT1080 cells)
containing 10% (v/v) resazurin dye. After 1 h of incubation at
37 °C, the absorbance of the medium was measured at 570 and
600 nm. Cell viability was calculated as a percentage of control
cells (nontransfected cells), according to the following
equation:
= − ′ − ′ ×A A A A
cell viability (%of control)
[( )/( )] 100570 600 570 600
where A570 and A600 are the absorbances of the samples, and
A′570 and A′600 are the absorbances of control cells, at the
indicated wavelengths.
■ RESULTS
Physicochemical Characterization of Complexes.
Because the efficacy to deliver genetic material inside target
cells is strongly dependent on the physicochemical properties
of the carrier systems, the different complexes used in the
present study were characterized with respect to their size and
surface charge density. As shown in Table 2, lipoplexes
prepared from DOTAP:DOPE (1:2 molar ratio) cationic
liposomes at the 1/1 lipid/DNA (+/−) charge ratio exhibited
the smallest mean diameter (approximately 240 nm) and the
most negative zeta potential (−27.1 mV). Binary complexes
prepared with the S413-PV or with the H5-S413-PV peptides at
different charge ratios (5/1 and 10/1) exhibited mean
diameters of 655 to 1400 nm, along with slightly positive
zeta potentials. Addition of DOTAP:DOPE (1:2 molar ratio)
cationic liposomes to any of the peptide/DNA complexes
resulted in a significant increase in the size of the resulting
complexes (approximately 2100−2700 nm), except for the
ternary complexes of the histidine derivative formulated at the
10/1/1 ratio, which maintained the same size as their binary
counterpart (665 nm). The surface charge values for these
complexes were generally positive and close to neutrality.
Plasmid DNA Delivery Mediated by S413-PV- and H5-
S413-PV-Based Vectors. In order to comparatively evaluate
the biological activity of the S413-PV peptide, previously used as
a component in plasmid DNA delivery systems,11 and that of a
new histidine-enriched derivative (H5-S413-PV), cell viability
and transfection experiments were performed in two tumoral
cell lines (HeLa and A549). Complexes of each peptide with a
plasmid DNA encoding the GFP gene were prepared, either per
se or in combination with DOTAP:DOPE (1:2 molar ratio)
liposomes, using the order of component addition that was
previously shown to originate complexes with the highest
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transfection ability.35 The viability of A549 and HeLa cells
(Figure 1) was determined following exposure to the peptide-
based binary complexes (S413-PV/pDNA or H5-S413-PV/
pDNA) and ternary complexes (S413-PV/pDNA/DOTAP:-
DOPE or H5-S413-PV/pDNA/DOTAP:DOPE), as well as to
DOTAP:DOPE/pDNA and lipofectamine/pDNA lipoplexes
(used as positive controls). HeLa cells (Figure 1A) were shown
to be more susceptible to complex-mediated cytotoxicity than
A549 cells (Figure 1B), particularly at the highest peptide/
DNA (+/−) charge ratios. The tested formulations did not
significantly affect the viability of A549 cells (Figure 1B),
especially when compared to that of the commercially available
transfection reagent Lipofectamine 2000. In HeLa cells, the
wild-type CPP (S413-PV) was more toxic than its histidine
derivative, when formulated both in binary and ternary
complexes. This cytotoxic effect was mostly significant for the
formulations with high peptide amounts, i.e., CPP/pDNA at a
10/1 charge ratio and CPP/pDNA/DOTAP:DOPE at a 10/1/
1 charge ratio. In these cases, the cell viability in the presence of
complexes containing the wild-type peptide was about 30% of
that observed in the presence of complexes prepared with the
new histidine-enriched peptide, although the former complexes
were more efficient in transfecting HeLa cells (see Figure 2A)
than the corresponding complexes prepared with the H5-S413-
PV peptide.
The ability of formulations assayed for cell viability, as
described in Materials and Methods, to transfect HeLa and
A549 cells was assessed by flow cytometry analysis. Figure 2
presents the percentage of transfected cells (A and C) and the
mean GFP fluorescence intensity (B) obtained with CPP-based
complexes in both cells lines. Regarding HeLa cells, a highly
transfectable cell line, the highest number of transfected cells
was achieved with the binary (80.1%) and ternary (77.7%)
complexes containing the wild-type CPP, prepared at 10/1 and
10/1/1 (+/−) charge ratios, respectively. Both values were
higher than that obtained with Lipofectamine 2000 (74.0% of
transfected cells). As observed, the H5-S413-PV peptide,
although unable to efficiently deliver plasmid DNA to HeLa
cells when formulated in a binary complex (achieving only
approximately 11% of transfected cells), was able to transfect a
considerable number of cells (approximately 60%) when
present in ternary complexes at 5/1/1 and 10/1/1 peptide/
pDNA/lipid charge ratios. Regarding the mean fluorescence
intensity, which represents the average amount of DNA copies
Table 2. Mean Diameter and Zeta Potential of the Plasmid
DNA Complexes
size (nm)a
zeta potential
(mV)a
DOTAP:DOPE/pDNA 1/1 239.4 (±47.1) −27.1 (±3.0)
S413-PV/pDNA 5/1 1412.0 (±485.4) +9.9 (±4.4)
S413-PV/pDNA 10/1 1191.3 (±176.7) +9.6 (±3.8)
H5-S413-PV/pDNA 5/1 1108.5 (±168.7) +9.6 (±4.4)
H5-S413-PV/pDNA 10/1 654.8 (±110.1) +12.3 (±4.5)
S413-PV/pDNA/DOTAP:DOPE
2/1/1
2628.6 (±401.9) +9.2 (±3.8)
S413-PV/pDNA/DOTAP:DOPE
5/1/1
2157.1 (±836.5) +0.3 (±5.0)
S413-PV/pDNA/DOTAP:DOPE
10/1/1
2348.2
(±938.6)**
+7.2 (±3.2)
H5-S413-PV/pDNA/DOTAP:DOPE
2/1/1
2627.8 (±435.4) +8.6 (±4.1)
H5-S413-PV/pDNA/DOTAP:DOPE
5/1/1
2762.7
(±359.1)***
+13.0 (±3.3)
H5-S413-PV/pDNA/DOTAP:DOPE
10/1/1
665.1 (±100.4) −5.6 (±2.8)
aResults represent the mean ± SD from three independent
experiments. Data comparisons were performed between formulations
containing S413-PV and H5-S413-PV (no significance) and between
S413-PV/pDNA or H5-S-S413-PV/pDNA and the corresponding
ternary complexes containing DOTAP:DOPE (**p < 0.01; ***p <
0.001).
Figure 1. Cell viability in the presence of different CPP-based gene delivery systems. HeLa (A) and A549 (B) cells were incubated with the different
complexes containing 1 μg/mL of GFP-encoding plasmid DNA for 4 h, following an additional 44 h of incubation with complete medium. After this
period, cell viability was determined by a modified Alamar Blue assay as described in Materials and Methods. Complexes of DNA with
DOTAP:DOPE and with Lipofectamine 2000 were used for comparison. Cell viability is expressed as a percentage of the control (nontransfected
cells). All results are presented as the mean ± SD of at least three independent experiments. Data comparisons were performed between
formulations containing S413-PV and H5-S413-PV (*p < 0.05; ***p < 0.001), between DOTAP:DOPE/pDNA lipoplexes and the same lipoplexes
containing S413-PV or H5-S413-PV (
###p < 0.001) and between S413-PV/pDNA or H5-S413-PV/pDNA and the corresponding ternary complexes
containing DOTAP:DOPE (§p < 0.05).
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delivered to each cell, the results indicated that the binary
complexes containing the S413-PV or H5-S413-PV peptide
delivered a low amount of plasmid copies per cell (Figure 2B).
However, ternary complexes containing the H5-S413-PV
peptide, prepared at the 5/1/1 and 10/1/1 charge ratios,
delivered a higher number of plasmid copies (reflected by a 8−
11-fold fluorescence increase relative to the nontreated control
cells) than the same formulations containing the wild-type CPP
(3−4-fold increase relative to the nontreated control cells).
These results indicate that the delivery ability of the complexes
was increased upon addition of DOTAP:DOPE (2:1 molar
ratio) liposomes, this increase being significantly more
pronounced in H5-S413-PV/pDNA formulations than in S413-
PV/pDNA formulations.
Parallel transfection experiments with ternary complexes
composed of either peptide at the 10/1/1 (+/−) charge ratio in
the presence of 10% serum were performed. Although the
percentage of transfected cells decreased 11% for complexes
formulated with the wild-type peptide, the cell viability was less
affected as compared to that observed in the absence of serum
(52% cell viability with serum vs 27% without serum). With the
histidine-derived peptide-containing complexes, cells main-
tained a high level of viability, and 33% of cells were
successfully transfected (data not shown).
Concerning A549 cells, S413‑PV peptide-containing binary
and ternary complexes were able to transfect a considerable
number of cells, only surpassed by Lipofectamine 2000 (Figure
2C). H5-S413-PV-based plasmid vectors, at the different charge
ratios assayed, showed similar or lower transfection efficiencies
as compared to those of the corresponding S413-PV/pDNA
complexes. For the transfection of these cells, neither S413-PV-
nor H5-S413-PV-based formulations benefited from the addition
of the lipid component. The fluorescence fold increase relative
to the nontreated control cells showed values lower than 1.6 for
Figure 2. Transfection efficiency mediated by different CPP-based systems in HeLa (A and B) and A549 (C) cells. Cells were incubated with the
different complexes containing 1 μg/mL of GFP-encoding plasmid DNA for 4 h at 37 °C, as described in Materials and Methods. Flow cytometry
analysis of live cells was performed 48 h after transfection to determine the percentage of transfected cells (A and C) and the increase in cell green
fluorescence (B) with respect to the control, nontreated cells, set to 1. Complexes of DNA with DOTAP:DOPE liposomes or Lipofectamine 2000
were used for comparison. All results are presented as the mean ± SD of at least three independent experiments. Data comparisons were performed
between formulations containing S413-PV and H5-S413-PV (*p < 0.05; ***p < 0.001), between DOTAP:DOPE/pDNA lipoplexes and the same
lipoplexes containing S413-PV or H5-S413-PV (
#p < 0.05, ##p < 0.01) and between S413-PV/pDNA or H5-S413-PV/pDNA and the corresponding
ternary complexes containing DOTAP:DOPE (§§p < 0.01; §§§p < 0.001).
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all tested conditions, being only significant for the binary
complexes composed of the histidine-enriched CPP at the 10/1
charge ratio (data not shown).
SiRNA Delivery Mediated by S413-PV- and H5-S413-PV-
Based Vectors. In order to select the peptides having the
most suitable features to be used in a gene silencing approach,
the cytotoxic effects of siRNA delivery systems generated by
complexation of the S413-PV peptide or one of its derivatives
(H5-S413-PV, reverse NLS, and scrambled) with a siRNA
targeting GFP were evaluated in HT1080 GFP-expressing cells
(Figure 3).
Significant differences were observed in the cytotoxicity
levels induced by binary complexes prepared with the different
peptides. The formulations containing S413-PV or its histidine
analogue displayed no relevant toxicity (89% and 100% cell
viability, respectively). However, cell viability decreased to
61.9% and 5.3% in the presence of complexes containing the
scrambled (S413‑PVscr) and the reverse NLS (S413-PVrev)
peptides, respectively. Therefore, these complexes were
discarded for the experiments of gene silencing, and only the
binary complexes that presented low toxicity profiles were
evaluated concerning their ability to deliver siRNA (using
confocal microscopy) and to induce GFP silencing (using flow
cytometry) in HT1080 cells.
Figure 4 displays the internalization pattern of Cy-3-labeled
siRNAs delivered to HT1080 cells through complexation with
S413-PV or H5-S413‑PV, after 4 (Figure 4A−C) or 24 (Figure
4D−F) hours of incubation. Representative flow cytometry
histograms (Figure 4G−I) reflecting GFP silencing upon
transfection with the same complexes are presented in parallel.
Figure 4J summarizes the silencing efficiency of the binary
formulations prepared with each of the four studied peptides, at
the 2/1 (+/−) charge ratio, as assessed by flow cytometry.
Confocal studies revealed that siRNA internalization
occurred at a similar extent for complexes containing the
S413-PV peptide and for those containing Lipofectamine 2000
(data not shown), although a more uniform distribution pattern
could be observed when the delivery system included the CPP.
However, the superior efficiency of S413-PV binary complexes
to mediate siRNA intracellular delivery was not accompanied
by an improved GFP knockdown (Figure 4H). In fact, only low
levels of biological activity were detected for siRNA/S413-PV
complexes. In contrast, the histidine-derivative peptide (H5-
S413-PV) was able to promote efficient intracellular siRNA
delivery (Figure 4C,F) while simultaneously mediating
significant GFP knockdown (Figure 4I). Complexes formulated
with this peptide promoted a 69% reduction of GFP levels,
while the other peptides did not induce significant silencing or
(in the case of S413-PV) induced nonspecific silencing (Figure
4J).
Following the same strategy previously employed to improve
S413‑PV-mediated pDNA
11 and oligonucleotide12 delivery,
DOTAP:DOPE (1:2 molar ratio) liposomes were added to
the formulations containing S413-PV peptide and siRNA, in an
attempt to enhance the RNA interference activity of these
peptides. Parallel experiments were performed with both the
scrambled and reverse NLS peptides in order to determine
whether the sequence and structure of this CPP would be
involved in the gene silencing activity of the complexes. All
possible orders of addition of the components of the ternary
complexes were tested, aiming at clarifying the importance of
the siRNA “wrapping” by the CPP or by the liposomes to the
biological activity of the CPP formulations. Figure 5 (panels A
and B) shows typical results obtained for GFP knockdown
mediated by the different generated systems. As observed, the
differences found in GFP expression when comparing
equivalent systems, containing either anti-GFP siRNAs or
mut siRNAs, were only significant for DOTAP:DOPE/siRNA
and S413-PV-containing systems (Figure 5A and B). It is also
possible to note that the protocol of preparation of the ternary
complexes did not play a crucial role in gene silencing
efficiency. In fact, the addition of cationic liposomes to
preformed CPP/siRNA complexes (Figure 5A) and the
addition of siRNAs to a mixture of cationic liposomes and
CPPs (Figure 5B) resulted in the formation of systems with
similar efficiencies, with the latter strategy being only slightly
superior. Although a third protocol involving the addition of
CPPs to preformed complexes of cationic liposome/siRNA was
found to be less efficient (data not shown), the resulting ternary
complexes still exhibited considerable biological activity.
When comparing the various CPP-based systems, generated
by the addition of siRNAs to a mixture of cationic liposomes
and the peptide (Figure 5B), the formulation containing the
S413-PV peptide was found to be the most efficient in mediating
GFP knockdown. Remarkably, this system was not only
significantly more efficient than DOTAP:DOPE/siRNA
complexes but also greatly superior to equivalent systems
prepared with the reverse NLS, scrambled, or H5-S413-PV
peptides. It should be noted that no significant GFP
knockdown was observed for H5-S413-PV ternary complexes
containing mut siRNAs.
Survivin Silencing in Different Human Cancer Cell
Lines Mediated by S413-PV- and H5-S413-PV-Based
Vectors. Following the demonstration of the feasibility of
Figure 3. Cell viability in the presence of S413-PV, S413-PVscr, S413-
PVrev, and H5-S413-PV peptide-based complexes at a peptide/siRNA
charge ratio of 2/1. HT1080 cells were incubated with the different
complexes containing 50 nM anti-GFP siRNA, and after 4 h of
incubation, the medium was replaced, and the cells were further
incubated for 44 h before analysis of cell viability by a modified Alamar
Blue assay, as described in Materials and Methods. All results are
presented as the mean ± SD of at least three independent
experiments.
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CPP-based delivery systems to mediate GFP knockdown in
HT1080 cells, the next step consisted of employing the
developed S413-PV and H5-S413-PV delivery systems to silence
the endogenous gene survivin using different human tumor cell
Figure 4. SiRNA internalization (A−F) and gene silencing efficiency (G−J) evaluated in vitro with different CPP-based systems. For cellular
internalization experiments, HT1080 cells (green) were incubated with S413-PV- or H5-S413-PV-based complexes containing 50 nM of mut Cy3-
labeled siRNA (red) at the 3/2 charge ratio. Cell nuclei were labeled with Hoechst 33342 dye (blue). Representative confocal microscopy images of
each experimental condition (630×), taken upon 4 (A−C) and 24 h (D−F) of cell incubation, are presented. Representative histograms of GFP
knockdown obtained by flow cytometry for the same formulations at 48 h post-transfection are also presented (G−I). Results for nontransfected
cells (NTC) are shown as a control. GFP knockdown mediated by S413-PV, S413-PVscr, S413-PVrev, or H5-S413-PV peptide-based complexes at a
peptide/siRNA charge ratio of 3/2 was quantified (J). HT1080 cells were incubated with the different complexes containing 50 nM of mut siRNA
(■) or anti-GFP siRNA (gray bar). After 4 h of incubation, the medium was replaced, and the cells were further incubated for 44 h before flow
cytometry analysis. Data presented in panel J are the mean ± SD of at least three independent experiments. Pairwise comparisons were performed
between formulations containing the anti-GFP siRNA and those containing the mut siRNA (###p < 0.001) and between S413-PVscr, S413-PVrev, or
H5-S413-PV formulations containing the anti-GFP siRNA and the S413-PV formulation containing the same siRNA (***p < 0.001). Results for
nontreated cells (NTC) were used as a control.
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lines toward their potential application in a target gene therapy
to cancer. In this context, survivin mRNA and protein levels
were determined by QRT-PCR and Western blot, respectively,
following the delivery of antisurvivin siRNAs by binary and
ternary complexes containing S413-PV or H5-S413-PV.
Figure 6 presents survivin mRNA levels 48 h upon cell
transfection with binary complexes, composed of peptide and
siRNA (Figure 6A), or with ternary complexes generated by the
addition of siRNA to a mixture of peptide and DOTAP:DOPE
liposomes (Figure 6B). The binary delivery systems achieved
variable silencing efficiencies, depending on the cell line and on
the peptide incorporated in the formulation. While formula-
tions containing the S413-PV peptide were unable to efficiently
decrease survivin mRNA levels in the three cell lines tested
(HT1080, A549, and HeLa; Figure 6A), complexes containing
the H5-S413-PV peptide presented different mRNA knockdown
Figure 5. GFP knockdown mediated by siRNA complexes prepared with S413-PV (wt), S413-PVscr (scr), S413-PVrev (rev), or H5-S413-PV (H5) and
DOTAP:DOPE liposomes at the peptide/lipid/siRNA 4/1/1.5 charge ratio, using two different protocols: addition of cationic liposomes to the
preformed CPP/siRNA complexes (A) or addition of siRNAs to a mixture of cationic liposomes and CPPs (B). HT1080 cells were incubated with
the different complexes containing 50 nM anti-GFP siRNA for 4 h at 37 °C. Parallel experiments were performed using mut siRNAs. Forty-eight
hours post-transfection, the efficiency of GFP knockdown mediated by the different complexes was evaluated by flow cytometry analysis of GFP
expression. All results are presented as the mean ± SD of at least three independent experiments. Pairwise comparisons were performed between
formulations containing the anti-GFP siRNA and the mut siRNA (*p < 0.05, **p < 0.01, and ***p < 0.001), between the DOTAP:DOPE/anti-GFP
siRNA formulation and equivalent formulations containing S413-PV, S413-PVscr, S413-PVrev, or H5-S413-PV (
##p < 0.01) and between the
lipofectamine/anti-GFP siRNA formulation and equivalent formulations containing S413-PV, S413-PVscr, S413-PVrev, or H5-S413-PV (
§§p < 0.01).
Results for nontreated cells (NTC) are shown as a control.
Figure 6. Survivin mRNA knockdown mediated by S413-PV and H5-S413-PV peptide-based complexes in HT1080, A549, and HeLa cells. (A) Binary
complexes of S413-PV/siRNA (■) or H5-S413-PV/siRNA (gray bar); (B) lipoplexes of DOTAP:DOPE/siRNA (□) and ternary complexes of S413-
PV/DOTAP:DOPE/siRNA (■) or H5-S413-PV/DOTAP:DOPE/siRNA (gray bar). Cells were incubated with the different complexes containing 50
nM antisurvivin siRNA for 4 h at 37 °C. Parallel experiments were performed using mut siRNAs. Forty-eight hours post-transfection, the efficiency
of survivin knockdown mediated by the different complexes was evaluated by quantitative PCR. For the determination of survivin mRNA levels,
RNA was recovered from cells 48 h post-transfection and converted to cDNA, which was analyzed by quantitative PCR. Survivin mRNA expression,
determined by the Pfaffl method, as described in the Materials and Methods section, is presented as the changes in RNA transcription caused by the
treatment with antisurvivin siRNAs, normalized to RNA transcription changes in cells treated with mut siRNAs (set to 1). All results are presented as
the mean ± SD of at least three independent experiments. Data comparisons were performed for each cell line between the formulations containing
S413-PV and H5-S413-PV (***p < 0.001) and between DOTAP:DOPE/siRNA lipoplexes and the same lipoplexes containing S413-PV or H5-S413-PV
(##p < 0.01; ###p < 0.001).
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values, varying from 0% silencing in HeLa cells to 50% in A549
cells and 70% in HT1080 cells (Figure 6A). In an attempt to
improve survivin silencing in A549 and HeLa cells,
DOTAP:DOPE liposomes (1:2 molar ratio) were added to
each CPP formulation by complexing the cationic liposomes
with the CPP prior to the addition of the siRNA. This strategy
was not tested in HT1080 cells based on the results from the
experiments on GFP silencing, where its application did not
result in any significant improvement (data not shown). Figure
6B shows that the ternary complexes containing the wild-type
or the histidine-derivative CPP decreased survivin mRNA levels
in the A549 cell line, resulting in 40% and 28% knockdown,
respectively. Application of this approach also led to promising
results in HeLa cells since 23% and 39% survivin mRNA
knockdown were observed for the wild-type and histidine-
enriched peptide-containing formulations, respectively. In both
cell lines, the silencing effect obtained with lipoplexes
containing exclusively the DOTAP:DOPE lipids and siRNA,
but no CPP, was negligible. In A549 cells, this formulation
appears even to mediate enhanced survivin expression.
Therefore, our results, showing a survivin knockdown of 23
to 40% in both cell lines with the ternary systems (S413-PV/
DOTAP:DOPE/siRNA and H5-S413-PV/DOTAP:DOPE/
siRNA), significantly superior to that obtained with DOTAP:
DOPE/siRNA complexes, suggest a clear advantage of
combining the S413-PV peptide or its histidine derivative with
the liposome formulation toward the generation of an efficient
nonviral siRNA-based antitumoral approach.
Figure 7 presents survivin protein levels, assessed by Western
blot analysis and normalized with α-tubulin levels, following
transfection with both binary and ternary complexes. A pattern
similar to that observed for mRNA expression was apparent
with binary complexes (Figure 7A). As observed, a superior
knockdown of survivin was achieved with complexes containing
the histidine-derivative peptide, although the results were only
statistically significant for HT1080 cells, in which survivin
protein levels decreased 44% (Figure 7A and C). Off-target
effects could be observed for binary complexes containing the
S413-PV since unspecific silencing was detected following
transfection with the mut siRNA, as displayed in Figure 7C.
Figure 7B shows survivin protein levels upon cell transfection
with ternary complexes containing the DOTAP:DOPE lipids in
addition to the CPP (S413-PV or H5-S413-PV) and siRNAs,
prepared as previously mentioned. No decrease in the protein
expression was achieved with these formulations or with the
lipoplexes without CPP, although a decrease in survivin mRNA
levels has been observed for the ternary complexes in both
A549 and HeLa cells (Figure 6B).
Figure 7. Survivin knockdown mediated by S413-PV and H5-S413-PV peptide-based complexes in HT1080, A549, and HeLa cells. (A) Binary
complexes of S413-PV/siRNA (■) or H5-S413-PV/siRNA (gray bar); (B) lipoplexes of DOTAP:DOPE/siRNA (□) and ternary complexes of S413-
PV/DOTAP:DOPE/siRNA (■) or H5-S413-PV/DOTAP:DOPE/siRNA (gray bar); (C) representative Western blot images illustrating the survivin
protein levels in nontreated HT1080 cells (NTC) or following siRNA (targeting survivin or siRNA mut) delivery by S413-PV or H5-S413-PV. Cells
were incubated for 4 h at 37 °C, with the different complexes containing 50 nM antisurvivin siRNA. The medium was then replaced, and the cells
were further incubated for 72 h before survivin and α-tubulin analysis. For each membrane, the analysis of band intensity was performed using Image
J software (Wayne Rasband National Institutes of Health, USA). Results in A and B are expressed as survivin fold change with respect to a control
(cells treated with the same formulation containing siRNA mut, which was set to 1). Data comparisons were performed for each cell line between
formulations containing S413-PV and H5-S413-PV (**p < 0.01). All results are presented as the mean ± SD of at least three independent experiments.
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■ DISCUSSION
Since the 1970s, when gene therapy was first described,36 great
efforts have been expended toward the discovery of appropriate
delivery systems able to surpass the cell membrane and release
the different types of nucleic acid molecules, ranging from long
DNA molecules to small double-stranded siRNAs, into the
target intracellular compartment. Despite the recent advances
concerning plasmid DNA and siRNA delivery to target cells,
further work should be developed to achieve high levels of
cellular uptake and long-term stability, while avoiding unspecific
effects, so that nucleic acid therapeutics can reach their full
potential as a clinically relevant option.37−40
One of the major obstacles for a successful gene therapy
strategy results from the impermeability of the cellular
membranes to most charged molecules, which has, however,
been surpassed by the use of vectors, including cell-penetrating
peptides. CPPs constitute a relatively new branch of nonviral
vectors that emerged following the description of the RNA/
DNA-binding domains of the human immunodeficiency virus
(HIV-1) Tat protein41 and of the Drosophila Antennapedia
homeodomain protein.42 Since then, several CPPs have been
described and used as delivery systems for nucleic acids and
other biomolecules.4 In the present study, an increase of the
length of the S413-PV peptide in five histidine residues was
performed taking into account previous observations with the
Tat peptide modified with histidine sequences of 5, 10, or 20
residues.6 On the basis of the fact that the S413-PV is a lysine-
rich peptide, lysine residues being mainly concentrated in the
NLS at the C-terminus of the peptide, the addition of five
histidine residues to the other end of the peptide would result
in a peptide close to the Tat peptide described by Lo et al.6 as
the most efficient (5His-Tat-5His) regarding the length and
positive charge distribution. The additional positive residues
have the capacity to facilitate endosomal release but may also
favor the establishment of electrostatic interactions between the
complexes and the cellular membrane, while potentially
increasing nucleic acid protection. The presence of the NLS
sequence, although free of histidine residues, added another
important function to the new peptide, which is to target
pDNA to the nucleus, thereby promoting its transcription.
The transfection efficiency and cell viability levels achieved
following pDNA delivery by S413-PV or H5-S413-PV complexes
diverged between the two tested cell lines. HeLa cells proved to
be more efficiently transfected than A549, although they are
also more severely affected in terms of the cytotoxicity exerted
by the complexes. In fact, the ability to transfect a high number
of cells is often associated with high cytotoxicity. This was also
observed with S413-PV-based binary and ternary complexes that
transfected the largest number of HeLa cells at charge ratios at
which they exerted the highest cytotoxicity, consistent with our
previous results.11 However, the same complexes produced
from the histidine-derivative peptide induced low levels of
toxicity in both cell types, even at high peptide concentrations
(Figure 1). Noteworthy, the H5-S413-PV ternary complexes
promoted an elevated percentage of transfected cells and levels
of transgene expression higher than those of corresponding
complexes with S413-PV (Figure 2B). This effect is most likely
linked to the endosomal escape process. The acidification of the
endosomal lumen will allow the protonation of the imidazole
group in the histidine residues, leading to osmotic swelling and
membrane destabilization.6,7 Moreover, it is possible that,
under the acidic conditions in the endosome, the peptide
undergoes conformational changes, which may enhance the
interaction of the complexes with the endosomal membrane
and consequent cytoplasmic release of DNA. This process
might have an important outcome in the free nucleic acid yield,
directly contributing to the amount of DNA that reaches the
cell nucleus. Studies on leucine- and alanine-rich peptides,
modified with histidine residues, showed that a histidine-
dependent, pH-driven transmembrane-to-in-plane peptide
orientation is correlated with high transfection efficiencies,9
suggesting that pH-dependent membrane insertion of the
peptides constitutes an important part of the DNA delivery
mechanism. Furthermore, the mechanism of cytoplasmic DNA
release may be mediated by membrane interactions with
peptide aggregates. Thus, “peptide micelles” may carry away a
few lipid molecules from the membranes generating transient
openings. Alternatively, peptide monomers or small oligomers
can insert efficiently into the membrane, leading to pore
formation.43
However, the high levels of transgene expression observed
for H5-S413-PV ternary complexes as compared to those of the
same complexes with S413-PV may be explained by an
enhanced uptake of the former. In this regard, complex
physicochemical properties, such as size and surface charge,
could be on the basis of different cellular uptake yields through
the preferential use of distinct internalization pathways.
However, in contrast with previous observations,11,44 phys-
icochemical characterization of the binary and ternary systems
revealed no significant differences in terms of size or charge
density between complexes with different transfection
efficiencies in HeLa cells. In fact, S4-13PV/pDNA complexes
at the 5/1 (+/−) charge ratio (1412.0 nm and +9.6 mV)
mediated efficient transfection as opposed to H5-S4-13PV/
pDNA complexes at the same charge ratio, which showed
similar size and zeta potential (1108.5 nm and +9.6 mV).
However, the lower levels of transfection in A549 cells relative
to HeLa cells suggest that these cell lines have different patterns
of interaction with the complexes, probably due to the different
proteoglycan content at the cell surface or to the preferential
use of different internalization pathways that may or may not
converge in the endolysosomal route.
The potential of complexes based on S413-PV peptide and its
derivatives to promote siRNA delivery was also addressed in
HT1080 GFP-expressing cells. In this regard, we aimed at
establishing the most suitable peptide structural features, which
warrant efficient siRNA-mediated gene knockdown without
causing cytotoxicity. Cell viability (Figure 3) indicates that the
peptide primary structure plays a crucial role in terms of the
cytotoxicity displayed by the corresponding peptide-based
complexes. Thus, the reverse NLS peptide, whose amino acid
sequence only differs from that of the original peptide in the
relative position of three amino acids of the NLS sequence,
produces much more toxic complexes compared to the
scrambled peptide, which preserves all the S413-PV amino
acid residues, although exhibiting a random order. However, as
can be observed in Table 1, the proline residue position in the
scrambled peptide is maintained with respect to the wild-type
and to the histidine-derivative peptides. Proline residues have
been suggested to play a relevant role in membrane protein
structure and dynamics.45,46 Proline presents its side chain
bonded to the tertiary nitrogen in a cyclic pyrrolidine ring,
which makes it the only mammalian imino acid. The
consequent absence of a proton in this residue impairs its
participation in the formation of hydrogen bonds. This feature
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fixes the peptide backbone around proline residues, providing a
kink or hinge that constrains the conformation of the adjacent
residues47 and leaves the neighboring carbonyl groups free to
participate in alternative hydrogen bonds.48 Therefore,
peptide−siRNA association and interaction of the resulting
complexes with the cellular membrane may be affected by the
different peptide conformations, which, in the case of the
reverse NLS peptide, could be caused by the change of location
of the proline residue, leading to a more cytotoxic effect.
The GFP knockdown experiments also shed light on the
mechanism of cytotoxicity associated with the use of complexes
containing the reverse NLS peptide; the off-target effects of
these complexes, reflected on the high silencing activity
obtained with the mut siRNA (79%), suggest that theses
complexes can strongly interfere with the cellular mechanisms
involved in protein synthesis, impairing the production of
proteins essential for normal cell function and thus resulting in
high toxicity.
The cell internalization extent of siRNA delivered by S413-PV
and H5-S413-PV peptide-based complexes, observed by confocal
microscopy, correlates with their silencing efficiencies (Figure
4). Consistently, the amount of siRNAs inside the cells
transfected with complexes of the wild-type peptide appears to
be lower than that inside the cells transfected with histidine-
derivative complexes. This observation might be explained by a
putatively higher affinity of complexes containing the H5-S413-
PV toward the cell surface proteoglycans.
In agreement with what has been previously observed for
oligonucleotides,12 S413-PV peptide/siRNA complexes did not
mediate significant gene silencing (Figure 4J). Also consistent
with previous studies for plasmid DNA and oligonucleotides,
ternary systems combining siRNAs with cationic liposomes and
cell-penetrating peptides displayed higher biological activity
than binary peptide/siRNA complexes,9,10 except for the
complexes containing the H5-S413-PV peptide (Figures 4J and
5B).
The results presented in Figure 5 show that the protocol of
preparation of the ternary complexes, specifically the order of
component addition, did not play a crucial role in their gene
silencing efficacy, although a small improvement in complex
efficiency could be obtained when combining cationic lip-
osomes with the cell-penetrating peptide prior to siRNA
addition. Most importantly, the systems containing the S413-PV
peptide showed superior biological activity with respect to
similar formulations including the reverse NLS or scrambled
peptides. This indicates that the amino acid sequence in the
S413-PV peptide is required to provide complexes with capacity
to promote siRNA internalization and silencing of the target
mRNA. The different efficiencies in GFP silencing displayed by
the systems containing the S413-PV and reverse NLS peptides
corroborate the previous assumption that the location of the
proline residue in the NLS sequence should be important for
the biological activity of the S413-PV-based complexes. In fact,
the NLS sequence per se would not be required for siRNAs to
accomplish their function since these molecules do not need to
reach the cell nucleus for silencing their target genes.
Since the relevance of a delivery system for potential clinical
application can only be fully evaluated in a therapeutic context,
we investigated the efficiency of the developed CPP-based
systems to mediate silencing of an endogenous gene encoding
an oncogenic protein (survivin). This protein presents a huge
potential as a therapeutic target in cancer therapy due to its
contribution to cancer survival, metastization, and cell
resistance to chemotherapy and radiotherapy.49 The binary
systems containing S413-PV were unable to decrease the mRNA
or protein levels of survivin in any of the three cell lines tested
(HT1080, A549, and HeLa). In contrast, similar complexes
generated from the H5-S413-PV peptide silenced the survivin
gene to different extents, depending on the cell line. The
highest knockdown effect was obtained in HT1080 cells (73%
decrease in mRNA and 44% decrease in protein levels). As
would be expected, the ability of the binary H5-S413-PV-based
complexes to silence the expression of survivin in HT1080 cells
was not statistically different from that observed for GFP (data
not shown). The different abilities of the H5-S413-PV peptide-
based complexes to silence the survivin gene in different cell
lines may be explained by specific features of cells, including
internalization preferred pathways, surface proteoglycans
content, and metabolic activity. In addition, the different levels
of survivin mRNA and protein expression among various tumor
cells50 may contribute to different silencing efficiencies.
Importantly, it was shown that the addition of DOTAP:DOPE
liposomes, both to S413-PV- and H5-S413-PV-containing
systems, led to an increase in mRNA silencing efficiency
(Figure 6B). Although the ability of ternary complexes to
silence survivin mRNA in both A549 and HeLa cells was
superior to that of DOTAP:DOPE/siRNA complexes, the
levels of protein knockdown did not follow the same pattern,
remaining similar to those observed in cells transfected with
lipoplexes devoid of CPP (Figure 7B). This may be due to
specific cellular mechanisms that regulate survivin levels in
cancer cells. In this regard, some studies have reported the
existence of an additional pool of survivin in mitochondria,
which can exert its action whenever the levels of cytoplasmic
survivin are lower than a defined threshold needed for cancer
cell survival.17,19,51
Nevertheless, a challenging finding in the present work was
that siRNA complexes containing the histidine-enriched S413-
PV peptide showed high competence to deliver siRNA into the
cells (as demonstrated in GFP-expressing HT1080 cells) and to
promote specific knockdown. However, in HeLa cells H5-S413-
PV-containing formulations exhibited a transfection efficiency
with plasmid DNA comparable to that showed by complexes
containing the wild-type peptide, with the advantage of
presenting a much lower cytotoxicity.
Overall, our findings reveal that the H5-S413-PV peptide
deserves to be further explored aiming at generating efficient
nucleic acid delivery-based strategies in the context of therapies
for cancer and other diseases. Moreover, our studies on the
development of new CPP-based nucleic acid delivery systems
and on the establishment of significant structure−activity
relationships may open new avenues toward in vivo application
of increasingly promising gene therapy approaches.
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